Exploring the Mechanism of Si-miao-yong-an Decoction in the Treatment of Coronary Heart Disease based on Network Pharmacology and
Experimental Verification

Jingmei      Zhang; Siming      Xue; Huan      Chen; Haixu      Jiang; Pengrong      Gao; Linghui      Lu; Qiyan      Wang

doi:10.2174/1386207326666230703150803

Abstract

Background: To investigate the active ingredients and the mechanisms of Si-miaoyong- an Decoction (SMYA) in the treatment of coronary heart disease (CHD) by using network pharmacology, molecular docking technology, and in vitro validation.

Methods: Through the Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), Uniprot database, GeneCards database, and DAVID database, we explored the core compounds, core targets and signal pathways of the effective compounds of SMYA in the treatment of CHD. Molecular docking technology was applied to evaluate the interactions between active compounds and key targets. The hypoxia-reoxygenation H9C2 cell model was applied to carry out in vitro verification experiments. A total of 109 active ingredients and 242 potential targets were screened from SMYA. A total of 1491 CHD-related targets were retrieved through the Gene- Cards database and 155 overlapping CHD-related SMYA targets were obtained. PPI network topology analysis indicated that the core targets of SMYA in the treatment of CHD include interleukin- 6 (IL-6), tumor suppressor gene (TP53), tumor necrosis factor (TNF), vascular endothelial growth factor A (VEGFA), phosphorylated protein kinase (AKT1) and mitogen-activated protein kinase (MAPK). KEGG enrichment analysis demonstrated that SMYA could regulate Pathways in cancer, phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) signaling pathway, hypoxiainducible factor-1(HIF-1) signaling pathway, VEGF signaling pathway, etc.

Results: Molecular docking showed that quercetin had a significant binding activity with VEGFA and AKT1. In vitro studies verified that quercetin, the major effective component of SMYA, has a protective effect on the cell injury model of cardiomyocytes, partially by up-regulating expressions of phosphorylated AKT1 and VEGFA.

Conclusion: SMYA has multiple components and treats CHD by acting on multiple targets. Quercetin is one of its key ingredients and may protect against CHD by regulating AKT/VEGFA pathway.

« Previous Next »

Graphical Abstract

[1]
Wirtz, P.H.; von Känel, R. Psychological stress, inflammation, and coronary heart disease. Curr. Cardiol. Rep.,  2017, 19(11), 111.
 [http://dx.doi.org/10.1007/s11886-017-0919-x] [PMID: 28932967]

[2]
Townsend, N.; Nichols, M.; Scarborough, P.; Rayner, M. Cardiovascular disease in Europe — epidemiological update 2015. Eur. Heart J.,  2015, 36(40), 2696-2705.
 [http://dx.doi.org/10.1093/eurheartj/ehv428] [PMID: 26306399]

[3]
Arenas de Larriva, A.P.; Limia-Pérez, L.; Alcalá-Díaz, J.F.; Alonso, A.; López-Miranda, J.; Delgado-Lista, J. Ceruloplasmin and coronary heart disease—A systematic review. Nutrients,  2020, 12(10), 3219.
 [http://dx.doi.org/10.3390/nu12103219] [PMID: 33096845]

[4]
Ren, Y.; Chen, X.; Li, P.; Zhang, H.; Su, C.; Zeng, Z.; Wu, Y.; Xie, X.; Wang, Q.; Han, J.; Guo, S.; Liu, B.; Wang, W. Si-Miao-Yong-An decoction ameliorates cardiac function through restoring the equilibrium of SOD and NOX2 in heart failure mice. Pharmacol. Res.,  2019, 146, 104318.
 [http://dx.doi.org/10.1016/j.phrs.2019.104318] [PMID: 31228552]

[5]
Su, C.; Wang, Q.; Zhang, H.; Jiao, W.; Luo, H.; Li, L.; Chen, X.; Liu, B.; Yu, X.; Li, S.; Wang, W.; Guo, S. Si-Miao-Yong-An decoction protects against cardiac hypertrophy and dysfunction by inhibiting platelet aggregation and activation. Front. Pharmacol.,  2019, 10, 990.
 [http://dx.doi.org/10.3389/fphar.2019.00990] [PMID: 31619988]

[6]
Zhao, Y.; Jiang, Y.; Chen, Y.; Zhang, F.; Zhang, X.; Zhu, L.; Yao, X. Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure. J. Ethnopharmacol.,  2020, 248, 112050.
 [http://dx.doi.org/10.1016/j.jep.2019.112050] [PMID: 31265887]

[7]
Qi, Z.; Li, M.; Zhu, K. Si-Miao-Yong-An on promoting the maturation of Vasa Vasorum and stabilizing atherosclerotic plaque in ApoE(-/-) mice: An experimental study.  Biomedicine & p. Pharmacotherapy,,  2019, 114, 108785.

[8]
Peng, L.; Li, M.; Xu, Y.; Zhang, G.; Yang, C.; Zhou, Y.; Li, L.; Zhang, J. Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model. J. Ethnopharmacol.,  2012, 143(1), 241-248.
 [http://dx.doi.org/10.1016/j.jep.2012.06.030] [PMID: 22750436]

[9]
Yan, S.K.; Liu, R.H.; Jin, H.Z.; Liu, X.R.; Ye, J.; Shan, L.; Zhang, W.D. “Omics” in pharmaceutical research: Overview, applications, challenges, and future perspectives. Chin. J. Nat. Med.,  2015, 13(1), 3-21.
 [http://dx.doi.org/10.1016/S1875-5364(15)60002-4] [PMID: 25660284]

[10]
Lima, A.M.; Siqueira, A.S.; Möller, M.L.S.; Souza, R.C.; Cruz, J.N.; Lima, A.R.J.; Silva, R.C.; Aguiar, D.C.F.; Junior, J.L.S.G.V.; Gonçalves, E.C. In silico improvement of the cyanobacterial lectin microvirin and mannose interaction. J. Biomol. Struct. Dyn.,  2022, 40(3), 1064-1073.
 [http://dx.doi.org/10.1080/07391102.2020.1821782] [PMID: 32990187]

[11]
Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform.,  2014, 6(1), 13.
 [http://dx.doi.org/10.1186/1758-2946-6-13] [PMID: 24735618]

[12]
Tao, W.; Xu, X.; Wang, X.; Li, B.; Wang, Y.; Li, Y.; Yang, L. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol.,  2013, 145(1), 1-10.
 [http://dx.doi.org/10.1016/j.jep.2012.09.051] [PMID: 23142198]

[13]
Xu, X.; Zhang, W.; Huang, C.; Li, Y.; Yu, H.; Wang, Y.; Duan, J.; Ling, Y. A novel chemometric method for the prediction of human oral bioavailability. Int. J. Mol. Sci.,  2012, 13(6), 6964-6982.
 [http://dx.doi.org/10.3390/ijms13066964] [PMID: 22837674]

[14]
UniProt. A hub for protein information. Nucleic Acids Res.,  2015, 43(Database issue), D204-D212.
 [PMID: 25348405]

[15]
Wang, N.; Zhu, F.; Shen, M.; Qiu, L.; Tang, M.; Xia, H.; Chen, L.; Yuan, Y.; Ma, S.; Chen, K. Network pharmacology-based analysis on bioactive anti-diabetic compounds in Potentilla discolor bunge. J. Ethnopharmacol.,  2019, 241, 111905.
 [http://dx.doi.org/10.1016/j.jep.2019.111905] [PMID: 31022565]

[16]
Eberhardt, J.; Santos-Martins, D.; Tillack, A.F.; Forli, S. AutoDock vina 1.2.0: New Docking methods, expanded force field, and python bindings. J. Chem. Inf. Model.,  2021, 61(8), 3891-3898.
 [http://dx.doi.org/10.1021/acs.jcim.1c00203] [PMID: 34278794]

[17]
Almeida, V.M.; Dias, Ê.R.; Souza, B.C.; Cruz, J.N.; Santos, C.B.R.; Leite, F.H.A.; Queiroz, R.F.; Branco, A. Methoxylated flavonols from Vellozia dasypus Seub ethyl acetate active myeloperoxidase extract: in vitro and in silico assays. J. Biomol. Struct. Dyn.,  2022, 40(16), 7574-7583.
 [http://dx.doi.org/10.1080/07391102.2021.1900916] [PMID: 33739225]

[18]
Chang, H.; Li, C.; Wang, Q.; Lu, L.; Zhang, Q.; Zhang, Y.; Zhang, N.; Wang, Y.; Wang, W. QSKL protects against myocardial apoptosis on heart failure via PI3K/Akt-p53 signaling pathway. Sci. Rep.,  2017, 7(1), 16986.
 [http://dx.doi.org/10.1038/s41598-017-17163-x] [PMID: 29209026]

[19]
Zhang, Q.; Shao, M.; Zhang, X.; Wang, Q.; Guo, D.; Yang, X.; Li, C.; Wang, Y. The effect of chinese medicine on lipid and glucose metabolism in acute myocardial infarction through PPARγ pathway. Front. Pharmacol.,  2018, 9, 1209.
 [http://dx.doi.org/10.3389/fphar.2018.01209] [PMID: 30405421]

[20]
Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem.,  2010, 31(2), 455-461.
 [PMID: 19499576]

[21]
Longde, W.; Ling, Y.; Yang, H.; Yi, Z.; Yongjun, W.; Xunming, J.; Xiaoyuan, N.; Qiumin, Q.; Li, H.; Yuming, X.; Mei, L.; Jiayi, S.; Jing, L.; Dong, Z. Fixed-dose combination treatment after stroke for secondary prevention in China: A national community-based study. Stroke,  2015, 46(5), 1295-1300.
 [http://dx.doi.org/10.1161/STROKEAHA.114.007384] [PMID: 25782466]

[22]
Foussas, S.G.; Tsiaousis, G.Z. Revascularization treatment in patients with coronary artery disease. Hippokratia,  2008, 12(1), 3-10.
 [PMID: 18923757]

[23]
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J.,  2008, 34(17), 1279-1291.
 [PMID: 18923757]

[24]
Li, L.; Chen, X.; Su, C. Si-Miao-Yong-An decoction preserves cardiac function and regulates GLC/AMPK/NF-κB and GLC/PPARα/PGC-1α pathways in diabetic mice. Biomed. Pharmacother.,  2020, 132, 110817.

[25]
Patel, R.V.; Mistry, B.M.; Shinde, S.K.; Syed, R.; Singh, V.; Shin, H.S. Therapeutic potential of quercetin as a cardiovascular agent. Eur. J. Med. Chem.,  2018, 155, 889-904.
 [http://dx.doi.org/10.1016/j.ejmech.2018.06.053] [PMID: 29966915]

[26]
Du, L.; Hao, M.; Li, C.; Wu, W.; Wang, W.; Ma, Z.; Yang, T.; Zhang, N.; Isaac, A.T.; Zhu, X.; Sun, Y.; Lu, Q.; Yin, X. Quercetin inhibited epithelial mesenchymal transition in diabetic rats, high-glucose-cultured lens, and SRA01/04 cells through transforming growth factor-β2/phosphoinositide 3-kinase/Akt pathway. Mol. Cell. Endocrinol.,  2017, 452, 44-56.
 [http://dx.doi.org/10.1016/j.mce.2017.05.011] [PMID: 28501572]

[27]
Devi, K.P.; Malar, D.S.; Nabavi, S.F.; Sureda, A.; Xiao, J.; Nabavi, S.M.; Daglia, M. Kaempferol and inflammation: From chemistry to medicine. Pharmacol. Res.,  2015, 99, 1-10.
 [http://dx.doi.org/10.1016/j.phrs.2015.05.002] [PMID: 25982933]

[28]
Feng, H.; Cao, J.; Zhang, G.; Wang, Y. Kaempferol attenuates cardiac hypertrophy via regulation of ASK1/MAPK signaling pathway and oxidative stress. Planta Med.,  2017, 83(10), 837-845.
 [http://dx.doi.org/10.1055/s-0043-103415] [PMID: 28219095]

[29]
Yang, J.T.; Qian, L.B.; Zhang, F.J.; Wang, J.; Ai, H.; Tang, L.H.; Wang, H.P. Cardioprotective effects of luteolin on ischemia/reperfusion injury in diabetic rats are modulated by eNOS and the mitochondrial permeability transition pathway. J. Cardiovasc. Pharmacol.,  2015, 65(4), 349-356.
 [http://dx.doi.org/10.1097/FJC.0000000000000202] [PMID: 25502309]

[30]
Koo, H.J.; Park, H.J.; Byeon, H.E.; Kwak, J.H.; Um, S.H.; Kwon, S.T.; Rhee, D.K.; Pyo, S. Chinese yam extracts containing β-sitosterol and ethyl linoleate protect against atherosclerosis in apolipoprotein E-deficient mice and inhibit muscular expression of VCAM-1 in vitro. J. Food Sci.,  2014, 79(4), H719-H729.
 [http://dx.doi.org/10.1111/1750-3841.12401] [PMID: 24689699]

[31]
Gao, L.; Yao, R.; Liu, Y.; Wang, Z.; Huang, Z.; Du, B.; Zhang, D.; Wu, L.; Xiao, L.; Zhang, Y. Correction to: Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway. Mol. Cell. Biochem.,  2022, 477(1), 327-328.
 [http://dx.doi.org/10.1007/s11010-021-04288-x] [PMID: 34741692]

[32]
Luo, Y.; Sun, G.; Dong, X.; Wang, M.; Qin, M.; Yu, Y.; Sun, X. Isorhamnetin attenuates atherosclerosis by inhibiting macrophage apoptosis via PI3K/AKT activation and HO-1 induction. PLoS One,  2015, 10(3), e0120259.
 [http://dx.doi.org/10.1371/journal.pone.0120259] [PMID: 25799286]

[33]
Hu, S.; Zhang, Y.; Zhang, M.; Guo, Y.; Yang, P.; Zhang, S.; Simsekyilmaz, S.; Xu, J.F.; Li, J.; Xiang, X.; Yu, Q.; Wang, C.Y. Aloperine protects mice against ischemia-reperfusion (IR)-induced renal injury by regulating PI3K/AKT/mTOR signaling and AP-1 activity. Mol. Med.,  2015, 21(1), 912-923.
 [http://dx.doi.org/10.2119/molmed.2015.00056] [PMID: 26552059]

[34]
Liu, G.; Zhang, B.; Hu, Q.; Liu, X.; Chen, J. Syringic acid mitigates myocardial ischemia reperfusion injury by activating the PI3K/Akt/GSK-3β signaling pathway. Biochem. Biophys. Res. Commun.,  2020, 531(2), 242-249.
 [http://dx.doi.org/10.1016/j.bbrc.2020.07.047] [PMID: 32798018]

[35]
Ding, Y.; Du, J.; Cui, F.; Chen, L.; Li, K. The protective effect of ligustrazine on rats with cerebral ischemia–reperfusion injury via activating PI3K/Akt pathway. Hum. Exp. Toxicol.,  2019, 38(10), 1168-1177.
 [http://dx.doi.org/10.1177/0960327119851260] [PMID: 31250662]

[36]
Li, Z.; Zhao, F.; Cao, Y.; Zhang, J.; Shi, P.; Sun, X.; Zhang, F.; Tong, L. DHA attenuates hepatic ischemia reperfusion injury by inhibiting pyroptosis and activating PI3K/Akt pathway. Eur. J. Pharmacol.,  2018, 835, 1-10.
 [http://dx.doi.org/10.1016/j.ejphar.2018.07.054] [PMID: 30075219]

[37]
Kaptoge, S.; Seshasai, S.R.K.; Gao, P.; Freitag, D.F.; Butterworth, A.S.; Borglykke, A.; Di Angelantonio, E.; Gudnason, V.; Rumley, A.; Lowe, G.D.O.; Jørgensen, T.; Danesh, J. Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. Eur. Heart J.,  2014, 35(9), 578-589.
 [http://dx.doi.org/10.1093/eurheartj/eht367] [PMID: 24026779]

[38]
Gigante, B.; Strawbridge, R.J.; Velasquez, I.M.; Golabkesh, Z.; Silveira, A.; Goel, A.; Baldassarre, D.; Veglia, F.; Tremoli, E.; Clarke, R.; Watkins, H.; Hamsten, A.; Humphries, S.E.; de Faire, U. Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease. PLoS One,  2015, 10(3), e0119980.
 [http://dx.doi.org/10.1371/journal.pone.0119980] [PMID: 25781951]

[39]
Perry, M.E. The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb. Perspect. Biol.,  2010, 2(1), a000968.
 [http://dx.doi.org/10.1101/cshperspect.a000968] [PMID: 20182601]

[40]
Wu, G.; Cai, J.; Han, Y.; Chen, J.; Huang, Z.P.; Chen, C.; Cai, Y.; Huang, H.; Yang, Y.; Liu, Y.; Xu, Z.; He, D.; Zhang, X.; Hu, X.; Pinello, L.; Zhong, D.; He, F.; Yuan, G.C.; Wang, D.Z.; Zeng, C. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation,  2014, 130(17), 1452-1465.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011675] [PMID: 25156994]

[41]
Zhang, Y.; Yang, X.; Bian, F.; Wu, P.; Xing, S.; Xu, G.; Li, W.; Chi, J.; Ouyang, C.; Zheng, T.; Wu, D.; Zhang, Y.; Li, Y.; Jin, S. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: Crosstalk between NF-κB and PPAR-γ. J. Mol. Cell. Cardiol.,  2014, 72, 85-94.
 [http://dx.doi.org/10.1016/j.yjmcc.2014.02.012] [PMID: 24594319]

[42]
Zhao, T.; Zhao, W.; Chen, Y.; Ahokas, R.A.; Sun, Y. Vascular endothelial growth factor (VEGF)-A: Role on cardiac angiogenesis following myocardial infarction. Microvasc. Res.,  2010, 80(2), 188-194.
 [http://dx.doi.org/10.1016/j.mvr.2010.03.014] [PMID: 20362592]

[43]
Yue, T.L.; Wang, C.; Gu, J.L.; Ma, X.L.; Kumar, S.; Lee, J.C.; Feuerstein, G.Z.; Thomas, H.; Maleeff, B.; Ohlstein, E.H. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ. Res.,  2000, 86(6), 692-699.
 [http://dx.doi.org/10.1161/01.RES.86.6.692] [PMID: 10747006]

[44]
Wang, N.; Han, Y.; Tao, J.; Huang, M.; You, Y.; Zhang, H.; Liu, S.; Zhang, X.; Yan, C. Overexpression of CREG attenuates atherosclerotic endothelium apoptosis via VEGF/PI3K/AKT pathway. Atherosclerosis,  2011, 218(2), 543-551.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2011.08.002] [PMID: 21872252]

[45]
Abeyrathna, P.; Su, Y. The critical role of Akt in cardiovascular function. Vascul. Pharmacol.,  2015, 74, 38-48.
 [http://dx.doi.org/10.1016/j.vph.2015.05.008] [PMID: 26025205]

[46]
Cadenas, S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic. Biol. Med.,  2018, 117, 76-89.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2018.01.024] [PMID: 29373843]

[47]
Matusiak, A.; Chałubiński, M.; Broncel, M.; Rechciński, T.; Rudnicka, K.; Miszczyk, E.; Walencka, M.; Strapagiel, D.; Gajewski, A.; Chmiela, M. Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammation. Arch. Med. Sci.,  2016, 1(1), 45-54.
 [http://dx.doi.org/10.5114/aoms.2015.50772] [PMID: 26925118]

[48]
Lee, S.I.; Lee, E.S.; El-Fiqi, A.; Lee, S.Y.; Kim, E-C.; Kim, H.W. Stimulation of odontogenesis and angiogenesis via bioactive nanocomposite calcium phosphate cements through integrin and VEGF signaling pathways. J. Biomed. Nanotechnol.,  2016, 12(5), 1048-1062.
 [http://dx.doi.org/10.1166/jbn.2016.2209] [PMID: 27305825]

[49]
Chu, N.; Viennet, T.; Bae, H.; Salguero, A.; Boeszoermenyi, A.; Arthanari, H.; Cole, P.A. The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling. eLife,  2020, 9, e59151.
 [http://dx.doi.org/10.7554/eLife.59151] [PMID: 32744507]

[50]
D’Andrea, L.D.; Iaccarino, G.; Fattorusso, R.; Sorriento, D.; Carannante, C.; Capasso, D.; Trimarco, B.; Pedone, C. Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl. Acad. Sci. USA,  2005, 102(40), 14215-14220.
 [http://dx.doi.org/10.1073/pnas.0505047102] [PMID: 16186493]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1386207326666230703150803	Print ISSN 1386-2073
Publisher Name Bentham Science Publisher	Online ISSN 1875-5402

Combinatorial Chemistry & High Throughput Screening

Exploring the Mechanism of Si-miao-yong-an Decoction in the Treatment of Coronary Heart Disease based on Network Pharmacology and Experimental Verification

Abstract Play Pause

Graphical Abstract

Related Journals

Abstract